Head-to-head · Cost-Efficiency Index
Unique Physique vs MEDVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Unique Physique
Shoppers comfortable inferring which drug they're buying from a dose ceiling rather than a named label.
Visit Unique PhysiqueMEDVi
Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.
Visit MEDViThe verdict
Unique Physique and MEDVi tie on the Cost-Efficiency Index at 62/100, so neither wins outright on the numbers, so choose on fit. Unique Physique: Shoppers comfortable inferring which drug they're buying from a dose ceiling rather than a named label. MEDVi: Shoppers who want compounded semaglutide with no contract and are budgeting on the $299 refill price, not the first-month sale price.
Worth knowing either way: CoreAge Rx is one of our partners and leads our leaderboard, where partners are listed first (Cost-Efficiency Index 94/100). See how it stacks up: CoreAge Rx vs Unique Physique.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Unique Physique | MEDVi |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 62/100 |
| Semaglutide / mo | $159/moAll doses, compounded | $299/moMonth-to-month refill price; first month $179, compounded |
| Tirzepatide / mo | $289/moAll doses, compounded | Not disclosed |
| Semaglutide / yr (modeled) | $1,908 | $3,588 |
| Tirzepatide / yr (modeled) | $3,468 | — |
| Coverage | Coverage not published | Not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #263 | #268 |
Unique Physique
62/100Where the value is
- No-contract, single flat monthly price at each tier rather than a shifting per-dose ladder
- Named Medical Director with a real, checkable credential: Reena John, DO
- States it provides consultations via 'Licensed Clinicians in the Patient's State,' implying state-matched prescribers
The tradeoffs
- The pricing page never explicitly names semaglutide or tirzepatide — which drug each tier covers is inferred from the dose ceiling, not stated by the company
- No compounding pharmacy is named anywhere reached, unusual for a compounded-GLP-1 provider
MEDVi
62/100Where the value is
- The FAQ states both numbers plainly: $179 for the first month and refills locked in at $299, covering the provider review, the medication and shipping
- No contract; you can cancel at any time by email or through the patient portal chat
- Names its partner pharmacies (Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding) and the medical groups behind its providers
The tradeoffs
- The $179 headline is a first-month "FALL Sale" price; every refill after that is $299
- Cancellation must reach support at least 72 hours before your next billing date, and monthly charges are never refunded once the month has started
Regulatory note: the FDA issued a warning letter to MEDVi, LLC dba MEDVi in February 2026. We still list and link to MEDVi; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.